BMS’ Breyanzi meets primary endpoint in Phase III lymphoma trial
These trial results indicate the first time a CD19-directed CAR T cell treatment showed promise in a second-line setting.
News
LoA Update: GSK’s Zejula sees boost in chances to transition to next development stage in BAP1-mutated and DDR-deficient tumours
GlaxoSmithKline’s Zejula (niraparib) Phase Transition Success Rate (PTSR) score rose in several solid tumours on...
Hawthorne Effect raises funding for platform to decentralise trials
The company plans to leverage the proceeds to expedite its growth and scale up operations.
Study finds J&J’s Covid-19 vaccine effective against viral variants
Data showed antibody and cellular immune responses against SARS-CoV-2 variants of concern as well as...
Selva’s Covid-19 drug shows activity against SARS-CoV-2 variants
SLV213 was equipotent against existing key variants, including the UK, South African and Brazilian variants.
Bayer studies cell and gene therapies for Parkinson’s disease
Bayer subsidiary BlueRock Therapeutics has dosed the first subject in an open-label Phase I clinical study of its pluripotent stem cell-derived dopaminergic neurons, DA01, to treat Parkinson’s disease. A neurodegenerative…
Pfizer trials lower Covid-19 vaccine dose in children
Pfizer has selected a lower dose of its Covid-19 vaccine, co-developed with BioNTech, for assessment in Phase II/III clinical trial involving children aged under 12. The company chose 10µg and…
Elligo Health acquires AI clinical research firm Root Health
Elligo Health Research has acquired artificial intelligence (AI) virtual assistant for clinical research firm Root Health for an undisclosed amount. The deal supports Elligo’s aim to create a technology-driven, healthcare-enabling…
Inovio to start Phase III efficacy trial of Covid-19 vaccine
Inovio has expanded its existing collaboration with Advaccine Biopharmaceuticals Suzhou to carry out a global Phase III segment of the ongoing Phase II/III INNOVATE trial of Covid-19 DNA vaccine candidate,…
AstraZeneca’s Calquence improves survival in CLL patients
AstraZeneca has reported final data from the Phase III ELEVATE-RR clinical trial of Calquence (acalabrutinib) in adults with chronic lymphocytic leukaemia (CLL) who received prior treatment. The trial involved a…
RedHill concludes enrolment in Phase II/III Covid-19 drug trial
RedHill Biopharma has concluded enrolment in the global Phase II/III study of oral drug opaganib (Yeliva, ABC294640) in hospitalised patients with severe Covid-19 pneumonia. A chemical entity, opaganib is designed…
